Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Read More on ITOS: ...

Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones. WATER ...

Domvanalimab (dom). The company’s most advanced asset is dom, an Fc-silent anti-TIGIT monoclonal antibody that is undergoing evaluation in three registrational trials for the treatment of ...

TIGIT drugs from Merck & Co, Bristol-Myers Squibb/Agenus, Gilead/Arcus, GlaxoSmithKline/iTeos Therapeutics and Mereo Biopharma are in clinical trials already. It remains to be seen if tiragolumab ...

This page features the latest news about the Iteos stock. Iteos Therapeutics stock hits 52-week low at $8.49 Iteos Therapeutics Inc. (NASDAQ: ITOS) stock has reached a 52-week low, touching down ...

Featured here, the Income Statement (earnings report) for Iteos Therapeutics Inc, showing the company's financial performance from operating and non operating activities such as revenue ...

You'll find Call and Put Strike Prices, Last Price, Change, Volume, Implied Volatility, Theoretical and Greeks for Iteos options for the expiration dates selected. Below this information you can also ...